Calidi Biotherapeutics, a biotechnology company focused on developing targeted immunotherapies, has priced its public offering for 15,197,500 shares of common stock or pre-funded warrants. The offering also includes Series A, B, and C Common Warrants, each comprising one share of common stock and a corresponding warrant.
The combined effective price for the offering is $0.40 per share and common warrant, generating approximately $6.1 million in gross proceeds. The common warrants have an exercise price of $0.60 per share and will expire at various intervals from the issuance date.
The proceeds from the offering will primarily be used for working capital, general corporate purposes, and pre-clinical and clinical trials. Ladenburg Thalmann & Co. Inc. is the sole placement agent for the offering.
The offering is being made through a registration statement filed with the Securities and Exchange Commission (SEC) and became effective on April 15, 2024. Copies of the preliminary and final prospectuses are available on the SEC’s website.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.